Treatment of Influenza A in Adolescents

First-Line Treatment Recommendation

The American Academy of Pediatrics recommends oseltamivir (Tamiflu) as the antiviral drug of choice for managing influenza infections in adolescents, with a standard adult dosing of 75 mg orally twice daily for 5 days 1, 2, 3
Oseltamivir can be taken with or without food, though administration with meals may improve gastrointestinal tolerability 1

The American Academy of Pediatrics recommends initiating treatment as soon as possible within 48 hours of symptom onset for maximum benefit, reducing illness duration by approximately 1-1.5 days and decreasing symptom severity by up to 38% 3, 4
Treatment should not be delayed while waiting for laboratory confirmation of influenza, as clinical diagnosis during flu season is sufficient and delays reduce effectiveness 4

Oseltamivir treatment reduces illness duration by approximately 17.6-29.9 hours in otherwise healthy patients 5, 6
Oseltamivir decreases the risk of complications, including pneumonia (50% reduction) and secondary bacterial infections 5, 6

Zanamivir (inhaled) 10 mg (two 5-mg inhalations) twice daily for 5 days is an equally acceptable alternative for patients aged 7 years and older who do not have chronic respiratory disease 1, 2, 3
Peramivir (IV) 600 mg as a single infusion is approved for adolescents 13-17 years with acute uncomplicated influenza, though it is typically reserved for patients who cannot take oral or inhaled medications 1, 2

Vomiting is the most common adverse effect, occurring in approximately 15% of treated patients versus 9% on placebo, but is typically mild, transient, and rarely leads to discontinuation 4
There is no established link between oseltamivir and neuropsychiatric events, despite historical concerns from Japan 4, 5, 6

Treatment is appropriate even for otherwise healthy adolescents during influenza season, as it reduces symptom duration and complications 2, 5
Oseltamivir is not a substitute for annual influenza vaccination, which remains the primary prevention strategy 6
Resistance to oseltamivir remains low (<5% in recent seasons), making it a reliable first-line choice 7, 8, 6

The American Academy of Pediatrics recommends oseltamivir 75 mg orally twice daily for 5 days as the antiviral drug of choice for adolescent patients, with treatment initiated as soon as possible, ideally within 48 hours of symptom onset, to maximize clinical benefit 9, 10
The medication can be taken with or without food, though administration with meals may improve gastrointestinal tolerability 9
Treatment should not be delayed while waiting for laboratory confirmation of influenza, as clinical diagnosis during flu season is sufficient and delays reduce effectiveness 10

Zanamivir (inhaled) 10 mg (two 5-mg inhalations) twice daily for 5 days is an acceptable alternative for patients aged 7 years and older who do not have chronic respiratory disease 9
Peramivir (IV) 600 mg as a single infusion is approved for adolescents 13-17 years but is typically reserved for patients who cannot take oral or inhaled medications 9
Baloxavir 40 mg orally as a single dose (for patients 40-80 kg) or 80 mg (for patients ≥80 kg) is another option for patients ≥12 years 9

Vomiting is the most common adverse effect, occurring in approximately 15% of treated patients versus 9% on placebo 11, 10
There is no established link between oseltamivir and neuropsychiatric events, despite historical concerns from Japan 11, 10

The standard 5-day treatment course should be completed even if symptoms resolve earlier 9

While optimal benefit occurs within 48 hours, treatment initiated after this window still provides benefit in patients with moderate-to-severe or progressive disease 11, 10